BUZZ-Atrium Therapeutics shares surge after completing $50 million equity financing
路透社2026/10/08 12:01On October 8, shares of heart disease drug developer Atrium Therapeutics (RNA.O) rose 11.3% to $8.83 in pre-market trading on Thursday after the company successfully raised $50 million. The biopharmaceutical company announced it has agreed to sell about 6.3 million shares and pre-funded warrants to institutional investors through a private placement at $7.93 per share. RNA’s shares closed down 0.8% at $7.93 on Wednesday and have fallen roughly 44% in the past month. The company plans to use the net proceeds for the development of its two main product candidates, other research projects, among other uses. Atrium expects that the funds raised, together with existing cash and investments, will be sufficient to support its operations through 2028. Leerink acted as the lead placement agent for this offering, with Cantor Fitzgerald, Barclays, and Wells Fargo participating as well. Based in San Diego, California, Atrium has signed collaboration agreements with Bristol Myers Squibb (BMY.N) and Eli Lilly (LLY.N), and has about 17.1 million shares outstanding. Atrium began public trading on February 27 (link), following a spinoff from Avidity Biosciences (link), which was subsequently acquired by Swiss pharmaceutical company Novartis (NOVN.S).
October 8 - ** Cardiac drug developer Atrium Therapeutics (RNA.O) saw its share price rise 11.3% to $8.83 in pre-market trading on Thursday, after the company successfully completed a $50 million fundraising round.
** The biopharmaceutical company said it had agreed (link) to sell approximately 6.3 million shares of stock and pre-funded warrants to institutional investors via a private placement at $7.93 per share.
** RNA’s share price closed down 0.8% at $7.93 on Wednesday, with a cumulative decline of around 44% over the past month.
** The company plans to use the net proceeds from the fundraising for R&D of its two key candidate products, as well as other research projects and related uses.
** The company expects that the proceeds from this fundraising, together with existing cash and investments, will be sufficient to fund operations through 2028.
** Leerink served as the lead placement agent on this offering, with Cantor Fitzgerald, Barclays, and Wells Fargo participating.
** Based in San Diego, California, Atrium has entered into collaboration agreements with Bristol Myers Squibb BMY.N and Eli Lilly LLY.N, and has about 17.1 million shares outstanding.
** Atrium began public trading on February 27 (link), having been spun off from Avidity Biosciences (link), which has since been acquired by Swiss pharmaceutical company Novartis NOVN.S.
(To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. As automatic translation may contain inaccuracies or lack required context, Reuters does not guarantee the accuracy of the automated translation. Automated translation is provided for reader convenience only. Reuters accepts no liability for any harm or loss arising from the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Updated version 2 - According to the Financial Times, Starbucks once considered acquiring Chipotle.
Additional details from the report were included. Reuters, October 8 – According to the Financial Times, citing people familiar with the matter on Thursday, Starbucks (SBUX.O) has explored the possibility of acquiring Chipotle Mexican Grill (CMG.N). If the deal materializes, it would merge two of the most well-known brands in the U.S. food industry and further deepen the connection between Starbucks CEO Brian Niccol and Chipotle—where Niccol established his reputation before running the coffee chain. The Financial Times, citing sources, reported that the coffee chain has been working with advisers in recent months to discuss a proposal to acquire Chipotle. Both Starbucks and Chipotle did not immediately respond to Reuters' requests for comment. Chipotle's market value is nearly $39 billion, its shares were up about 4% in early trading, while Starbucks' stock fell about 3%. According to data from LSEG, Starbucks' market value is around $107 billion. Niccol was hired to revitalize the coffee chain, and over the past two years, he has focused on enhancing customer experience by simplifying menus and reducing wait times, leading to same-store sales growth for four consecutive quarters. Meanwhile, the Mexican grill chain is facing the dual challenges of weakening consumer demand and rising input costs amid persistently high inflation. (For the convenience of non-native English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may contain errors or miss important context, Reuters does not guarantee the accuracy of the automated text, which is provided solely for reader convenience. Reuters is not liable for any damages or losses resulting from the use of automated translation.)
US Stock Movement | Chip Stocks Generally Fall, Intel (INTC.US) Drops Over 3%
On Thursday, chip stocks generally declined. Intel (INTC.US) fell over 3%, and SanDisk (SNDK.US) dropped nearly 3%.
Updated version 1 - The Financial Times reports that Starbucks once considered acquiring Chipotle
Reuters reported on October 8, citing sources from the Financial Times, that Starbucks (SBUX.O) had explored the possibility of acquiring Chipotle Mexican Grill (CMG.N). As background, Starbucks CEO Brian Niccol previously led Chipotle and is widely credited with transforming the burrito chain into one of the strongest growth companies in the industry. Both Starbucks and Chipotle did not immediately respond to Reuters' request for comment. Starbucks, with a market capitalization of around $39 billions, saw its share price decline by about 3%, while Chipotle’s stock price rose by approximately 4%.
BUZZ - Goldman Sachs turns bullish, Palantir shares rise
On October 8th, Palantir Technologies (stock code: PLTR.O), a data analytics software provider, saw its shares rise by 3.7% to $201.26 in early trading Thursday, after Goldman Sachs upgraded its rating from “Neutral” to “Buy.” The firm set a target price of $230, representing approximately an 18% upside from the previous trading day’s closing price. Goldman Sachs stated that, based on recent discussions with industry experts, its main conclusion is that the stock is expected to enter a new phase of outperformance before 2027. The bank noted that with PLTR shifting towards sovereign AI, customized applications, and its new verticalization strategy, its total addressable market “may be on the verge of another step-change in depth.” Goldman Sachs also mentioned that, given the stock’s underperformance in 2026, its enterprise value/free cash flow (EV/FCF) multiple is currently lower than that of peer growth companies. With Thursday’s rally, PLTR’s share price has increased about 13% this year, lagging behind the Nasdaq .IXIC index’s 18% gain; the current price is about 3% lower than the all-time intraday high of $207.52 set on November 3, 2025. According to LSEG data, among the 33 brokers covering the stock, 24 rate it as “Strong Buy” or “Buy,” 7 as “Hold,” and 2 as “Sell” or “Strong Sell.” The median target price is $212.50, up from $195 three months ago. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Automated translation may be inaccurate or may not capture the needed context, and Reuters does not guarantee the accuracy of automated translation. Automated translation is provided solely for readers’ convenience. Reuters accepts no liability for any damage or loss resulting from use of the automated translation function.)
